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Compared with triple assessment for symptomatic and occult breast disease, magnetic resonance mammography (MRM) offers
higher sensitivity for the detection of multifocal cancer, which is important in selecting patients appropriately for breast-conserving
surgery. It is an ideal tool for the screening of patients with a high risk of breast cancer or where there is axillary disease or nipple
discharge and conventional imaging has not revealed the primary focus. Techniques are now available to biopsy lesions only apparent
on MRM. MRM can differentiate scar tissue from tumour; therefore, it is useful in patients in which there is possible recurrent disease.
Clinical and X-ray mammographic assessment of response to neoadjuvant chemotherapy may be unreliable because of replacement
of the tumour with scar tissue. MRM can identify responders and nonresponders with more accuracy. It is the modality of choice for
the assessment of breast implants for rupture with accuracy higher than X-ray mammography and ultrasound. Advances in both
spatial and temporal resolutions, the imaging sequences employed, pharmacokinetic modelling of contrast uptake, the use of
dedicated and now phased-array breast coils, and gadolinium-based contrast agents have all played their part in the advancement of
this imaging technique. Despite the limitations of patient compliance, scan-time and cost, this review describes how MRM has become
a valuable tool in breast disease, especially in cases of diagnostic uncertainty. However, MRM must make the transition from research
institutions into routine clinical practice.
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The use of magnetic resonance imaging (MRI) in the evaluation of
breast disease has continued to gain recognition over the last 15
years, although mainly in research institutions. However, despite
its apparent advantages, magnetic resonance mammography
(MRM) still awaits introduction into routine clinical practice.
MRM relies on the presence of well-established morphological
features that help distinguish malignant from benign lesions. In
addition, angiogenesis induced by cancers is demonstrated by
dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI). Areas of increased microvessel density are delineated
following intravenous gadolinium–diethylenetriaminepentaacetic
acid (Gd–DTPA). The enhancement in malignant tissue is thought
to be because of increased permeability, vascularity and increased
interstitial space (Vaupel, 1994) (Figure 1)
In dynamic imaging areas of parenchymal deformity in the
breast may be re-imaged over time, thus allowing the signal-
intensity – time curve to be analysed in great detail. Fast scanning
techniques now make it possible to image preselected areas of the
breast at least every 2s. Curve analysis can be carried out by a
number of techniques, most typically by empirical methods or
pharmacokinetic modelling.
Kuhl et al reported a correlation between the shapes of the
signal-intensity curves and the likely aetiology. The curves were
subdivided into four categories. Types Ia or Ib are typical of
benign lesions, and types II and III are consistent with malignant
lesions. Using this method, Kuhl reported a sensitivity of 91%, a
specificity of 83% and an accuracy of 86% in distinguishing benign
from malignant lesions (Kuhl et al, 1999) (Figure 2).
Pharmacokinetic modelling is a mathematical process that uses
all the signal intensity data to give numeric values of the
permeability and the contrast exchange rate between the plasma
and the extravascular and extracellular space of a lesion. These
data can be used to differentiate benign from malignant lesions
objectively (Buckley et al, 1994) (Figure 3).
SYMPTOMATIC DISEASE
Currently, triple assessment is the gold standard for symptomatic
breast disease. In our centre, we have compared the evaluation of
285 symptomatic patients presenting to the breast clinic by both
the triple assessment and MRI. The sensitivity of each modality
was as follows: clinical examination 84%, mammography 87.6%,
fine-needle aspiration cytology 79.1%, triple assessment 99.2% and
MRI 99.2%. In addition, histologically confirmed multifocal
disease was detected by MRI in 40 patients, but in only nine
patients (22.5%) on mammography. The specificity for the
diagnosis of benign disease was as follows: clinical examination
83.1%, ultrasound 88.9%, mammography 86.4%, fine-needle
aspiration cytology 97%, triple assessment 59.1% and MRI
90.9%. We concluded that DCE-MRI of the breast is as sensitive
and more specific than the combined traditional triple assessment
for the diagnosis of malignant breast lesions (Drew et al, 1999b).
Similar findings have been reported in several other studies
(Table 1). *Correspondence: Mr PJ Drew; E-mail: pjdrew@hull.ac.uk
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The accurate staging of primary breast cancer is paramount. The
surgical plan depends upon the size and position of the mass. The
presence of multiple tumours in the same quadrant (multifocal) or
in multiple quadrants (multicentric) must be determined. Mam-
mography is still the main imaging modality in breast cancer with
sensitivity between 69 and 90% and the specificity ranging from 10
to 40% (Rankin, 2000). Tumours may be missed because of
observer error, dense breast tissue or even poor technique. Using
dynamic MRI of the breast, sensitivities are in excess of 95%, with
specificities over 80% (Turnbull, 2000). In a recent study by
Fischer et al, 16% of candidates for breast-conserving surgery had
clinically relevant findings at MR examination (Fischer et al, 1999).
In a similar but smaller study, Tan et al analysed the impact of
MRI on the surgical management of 83 patients being considered
for breast-conserving surgery. MRI altered the management in
18% of the patients (Tan et al, 1999).
We evaluated the accuracy of triple assessment compared with
MRI for the detection of multifocal disease prior to breast surgery.
The resultant sensitivity, specificity, positive and negative
predictive values were 18, 100, 100 and 76% for triple assessment
and 100, 86, 73 and 100% for DCE-MRI. The study also identified a
subgroup of breast cancer patients with multifocal/multicentric
disease not evident on standard triple assessment (Drew et al,
1999a).
COMICE TRIAL
The clinical relevance of preoperative detection of small additional
carcinomas by MRI, especially small foci of DCIS has yet to be
answered. Should these cancers be excised or would adjuvant
radiotherapy treat them satisfactorily? The UK-based comparative
effectiveness of MR imaging in breast cancer (COMICE) trial has
just commenced. This is a randomised control trial recruiting
patients planned for wide local excision for primary breast cancer
into two study arms. One group of patients will undergo standard
imaging and the other group will have additional preoperative MRI
staging. This trial will also clarify whether patients scheduled for
conservative breast surgery are being adequately staged as the
Figure 1 A T1-weighted image of an invasive breast cancer (A) fat-
saturated image after gadolinium contrast (B).
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Figure 2 Shapes of signal-intensity curves and likely histology (Kuhl et al,
1999).
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Figure 3 Typical malignant and benign lesion signal-intensity curves (data
points) and two-compartment pharmacokinetic modelling (lines).
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Specialist Group meeting, 2000).
Screening X-ray mammography has resulted in the detection of
increasing numbers of T1b breast lesions, tumour diameter
40.5cm and p1cm (Beahrs, 1992). There are little data in the
literature regarding the accuracy of diagnosis in sub-T1b breast
lesions by any of the routinely used imaging modalities, namely X-
ray mammography, ultrasound or MRI. In a recent study of 63
patients, we evaluated the accuracy of diagnosis of clinically occult
sub-1cm lesions using DCE-MRI and achieved a sensitivity of
93.2% and a negative predictive value of 84.6% in differentiating
benign from malignant sub-1cm lesions (Kneeshaw et al, 2001a).
Therefore, DCE-MRI may have a role following failed stereotactic
biopsy or ultrasound-guided core biopsy in patients with very
small lesions instead of proceeding to open localised surgical
biopsy.
MR-GUIDED BREAST BIOPSY AND LOCALISATION
The high sensitivity of MRI sometimes means that abnormalities in
the breast are detected that cannot be imaged using X-ray
mammography or ultrasound. Therefore, MR-guided biopsy
techniques are currently being developed. Open configuration
scanners allow continuous access to the patient but are limited by
low field strength which compromises signal-to-noise ratio (Gould
et al, 1998). Heywang-Kobrunner et al described a unilateral open-
breast coil. This allowed successful hook wire placement in 10 out
of 11 patients with an average lesion size of 12mm (Heywang-
Kobrunner et al, 1994). Closed magnet systems allow access to the
patient outside the bore of the magnet with a localisation device.
Early small studies using freehand and localisation devices have
been encouraging. Daniel et al managed to obtain diagnostic tissue
in all 27 lesions using a freehand method. Liney et al (2000)
advocated the use of carbon-fibre-core biopsy needle to reduce
artefact. In a larger series of 59 patients with lesions only visible on
MRM, Kuhl et al (2001) achieved a diagnostic accuracy of 98%
using MR-guided stereotactic large-core (14 G) needle biopsy.
SCREENING
Breast MRI, with its high sensitivity, is potentially an ideal tool for
the screening of high-risk populations. It is especially useful in
younger women because of the lower sensitivity of X-ray
mammography in this group. Stoutjesdijk et al published results
in 2001 comparing MRI and mammography in women with a
hereditary risk of breast cancer. In a retrospective study of 179
women at high risk of breast cancer, MRI demonstrated 13
cancers, seven of which were not demonstrated by mammography.
Receiver operator curves areas for MRI and mammography were
0.99 and 0.74, respectively (Stoutjesdijk et al, 2001). Warner et al
(2002) compared MRI, mammography and ultrasound for
surveillance of 196 women with proven BRCA1 or BRCA2
mutations or strong a strong family history of breast cancer. All
six invasive breast cancers were picked up by MRI with
mammography and ultrasound detecting 2 and 3, respectively
(Warner et al, 2002).
The UK magnetic resonance imaging for breast screening
(MARIBS) trial is a multicentre ongoing trial comparing X-ray
mammography and MRI as a method for screening genetically
high-risk women. Women aged 35–50 years with BRCA1 or
BRCA2 or aged 25–50 years with TP53 are being recruited.
Furthermore, this study is examining women’s attitudes to MR
examination of the breast (Brown et al, 2000).
RESPONSE TO CHEMOTHERAPY
Patients with locally advanced disease at presentation are more
commonly undergoing neoadjuvant chemotherapy followed by
surgery. It is the aim of the treatment to shrink the tumour to allow
subsequent mastectomy or breast-conserving surgery (Jacquillat
et al, 1989). Evaluation of the response to chemotherapy by
conventional imaging methodology is difficult. This is because of
changes induced in the breast parenchyma, including the
replacement of tumour with diffuse fibrosis. The fibrotic tissue
may be confused with residual tumour on palpation. Breast MRI is
more effective than X-ray mammography at determining the extent
of residual disease following neoadjuvant chemotherapy (Esser-
man et al, 1999; Drew et al, 2001) (Figure 4).
Tissue permeability may be evaluated using dynamic breast MRI
and this can be used to predict patients who will respond to
chemotherapy (Hayes et al, 2002). Predicting tumour response
may allow drugs to be altered early in treatment.
DCIS
The advent of breast screening has shown that in situ disease with
or without microinvasion represents 20–25% of all screen-
detected breast cancer (Roberts et al, 1990). The MR appearance
of microcalcification, the cardinal mammographic feature of DCIS
is a signal void. However, in a similar manner to invasive disease,
DCIS induces angiogenesis and this can be detected in vivo by
DCE-MRI (Figure 5). In a study by Gilles et al (1995), dynamic
MRI showed contrast enhancement in 34 out of 36 patients with
DCIS. Other MR studies have reported variable accuracy for
classification of microcalcification. Westerhof et al (1998),
investigating mammographically suspicious microcalcifications,
reported a sensitivity of 45%, specificity of 72%, positive predictive
value of 71%, negative predictive value 46% and an accuracy of
56%, and in a further study, Gilles et al observed a sensitivity of
95% and a specificity of 51%. Their specificity was impaired
because the presence or absence of contrast uptake in the breast
was the only parameter used to decide if the area of micro-
calcification was associated with malignancy or not (Gilles et al,
1996).
Malich et al looked specifically at 100 mammographically
suspicious lesions using different imaging modalities. He showed
Table 1 Selected published results of breast MRI
Author Year Number of lesions Number of cancers Sensitivity Specificity
Heywang (Heywang-Kobrunner et al, 1989) 1989 150 71 0.98 0.65
Kaiser (Buckley et al, 1997) 1989 191 58 1.0 0.97
Gilles (Bradley et al, 2000) 1994 143 64 0.95 0.53
Orel (Orel et al, 1995) 1995 166 64 0.92 0.88
Bone (Brown et al, 2000) 1997 238 145 0.92 0.72
Drew (Drew et al, 1998) 1998 105 9 1.0 0.93
Lui (Liu et al, 1998) 1998 120 70 0.93 0.74
Malich (Malich et al, 2001) 2001 90 62 0.98 0.81
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predictive value of 88% and negative predictive value of 97% for
malignant disease, while the corresponding values for DCIS and
hyperplasia were 86, 83, 75 and 91%, respectively (Malich et al,
2001).
We are currently evaluating the use of DCE-MRI in the
assessment of screening-detected mammographically indetermi-
nate microcalcifications and initial results for differentiating
benign from malignant causes are encouraging. In a cohort of 42
patients, we achieved a sensitivity of 87.5% and a negative
predictive value of 80% (Kneeshaw et al, 2001b).
RECURRENT DISEASE
Areas of scar tissue following breast-conserving surgery can
simulate recurrences on mammography. MRI performed up to 1-
year post-surgery shows some enhancement in the scar tissues at
dynamic examination making the differentiation of scar from
recurrence unsatisfactory. After 12 months, however, MRI can be
used to detect or exclude recurrent tumour with high sensitivity.
Kramer et al (1998) reported a sensitivity of 91% for detection of
cancer recurrence with MRI compared to 51, 67 and 83% for
physical examination, X-ray mammography and ultrasound,
respectively, in 33 cases of tumour recurrence. We evaluated
clinical examination, mammography and MRI in the detection of
recurrent tumour following breast-conserving surgery. The
sensitivity of clinical examination, mammography, examination
combined with mammography, and MRI alone for the detection of
recurrent cancer were 89, 67, 100 and 100%, respectively, with
specificity values of 76, 85, 67 and 93%. We concluded that
combined clinical examination and mammography were as
sensitive as dedicated dynamic MR of the breast for the detection
of locoregional recurrence, but that breast MRI was associated with
a far greater specificity (Drew et al, 1998).
This year Belli et al evaluated 40 women with clinical or
radiological evidence of local recurrence (Belli et al, 2002). MRI
identified all the 22 cancers and showed 95% accuracy, 100%
sensitivity, 88.8% specificity with 5% false positives and 100%
negative predictive values.
There are no studies to date evaluating the use of MR for
monitoring patients after breast-conserving surgery. However,
the Board of the Faculty of Clinical Radiology from The Royal
College of Radiologists in their Guidance on Screening and
Symptomatic Breast Imaging published 1999 stated that where
conventional triple assessment has been unhelpful in the assess-
ment of patients with suspected recurrences, MRI has been shown
to be useful.
Figure 4 Monitoring the response to neo-adjuvant chemotherapy.
Before treatment (A) and response after 3 months (B).
Figure 5 T1-weighted image of DCIS (A) and fat-saturated image after
gadolinium contrast (B) with malignant signal-intensity curve of enclosed
area.
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Breast cancer may present as an axillary metastasis with normal
triple assessment. MRI has been used in this setting to detect the
primary cancer. In one such study Orel et al (2000b) demonstrated
the primary cancer in 19 out of 22 patients who presented with an
axillary metastasis.
Clinical examination is generally poor in evaluating the axilla for
recurrent tumour. Bradley et al evaluated the accuracy of axillary
MRI in distinguishing between recurrent tumour and treatment-
induced effects. In their series using MRI, the specificity and
sensitivity for the detection of axillary metastasis was 100 and 89%,
respectively (Bradley et al, 2000).
NIPPLE DISCHARGE
Nipple discharge, although usually benign in origin, causes
concern because of the possibility of an underlying cancer.
Worrying features such as spontaneous, unilateral discharge in
which the fluid is bloody, serous or clear warrants further
evaluation. In a study by Orel et al (2000a), the use of MRI in
the investigation of nipple discharge was evaluated. Mammo-
graphic findings proved negative in 22 out of 23 patients while in
73% of the patients, MR findings correlated with the pathology
findings. They concluded that MR imaging could help identify
both malignant and benign causes of nipple discharge (Orel et al,
2000a).
BREAST IMPLANTS
MRI is widely regarded as the investigation of choice for the
demonstration of intracapsular and extracapsular breast implant
ruptures. The sensitivity of MR for the detection of implant
rupture is around 95% with a specificity of 90% and is
considerably better than mammography or ultrasound (Turnbull,
2000). The intracapsular rupture is recognised by the presence
of the linguine sign, which is caused by extensive folding of
the collapsed shell of the implant (Gorczyca et al, 1994). Free
silicone may be seen in the parenchyma of the breast following
an extracapsular tear with silicone-specific MRI sequences
(Figure 6).
PRACTICAL LIMITATIONS
The patient is required to remain still within the scanner for
around 20min for a standard dynamic MR series. Patients who are
large or have other medical problems may not tolerate these
conditions reducing the quality of the examination. Careful and
considerate patient positioning may help to overcome these
problems.
Patients with claustrophobia may initially refuse to enter the
scanner. Careful explanation about the examination often helps to
overcome these problems. Breast scanning is generally performed
with the patient prone and the breasts positioned in the cups of the
dedicated breast coil. This position is often well tolerated by
anxious patients, as they can see out of the magnet, but in severe
cases a light sedative may be administered. However, in our centre,
sedation has never been required for a breast MR examination
because of the favourable patient positioning. If one examines MRI
of all body parts, the sedation rate is approximately 4%.
Gadolinium contrast must be given intravenously during the
examination. Previous allergy to Gd–DTPA is a contraindication;
however, true anaphylactic shock following gadolinium adminis-
tration occurs in only 0.0003% of patients (Niendorf et al, 1998).
Previous surgery, especially cardiac, may cause image distortion
because of metal artefact from valves or sternal closure wire.
Absolute contraindications to MRI are mainly because of the
presence of ferromagnetic materials. Any non-MRI compliant
implant needs to be investigated for MRI compatibility. Any
suspicion of a metal injury including foreign bodies in the eye or
injuries from shrapnel needs to be excluded.
Following the initial financial outlay for an MR scanner, the
running costs are still significant with an average scan costing
around d350 including contrast agents.
SPECIFICITY ISSUES
MRI of the premenopausal breast may suffer reduced specificity
because of the presence of ‘hormone reactive’ parts of the breast.
These ‘pseudo-lesions’ enhance following Gd–DTPA variably
throughout the menstrual cycle. Kuhl et al (1997) reported that
the least troublesome time for scanning is within week 2 of the
menstrual cycle. The use of hormone replacement therapy will also
alter enhancement of the breast (Reichenbach et al, 1999).
Figure 6 Silicone-specific series showing an extracapsular tear with
silicone globules in soft tissues.
Figure 7 T1-weighted postcontrast fat-suppressed image of a breast
showing signal voids from surgical instrument metal fragments.
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of false positives as they can enhance in a similar way to malignant
lesions. The commercially available Gd-chelates are extracellular,
nontissue-specific compounds that leak out of the intravascular
space. New macromolecular contrast agents leak through cancer
microvessels, but do not leak through the endothelial barrier of
benign tumours (Gerlowski and Jain, 1986). These blood-pool
contrast agents are currently being developed. These may provide a
marked improvement in the ability to examine the macrocirculation
as well as microcirculation and thereby increase specificity.
Although DCE-MRI has been shown to be effective in distinguish-
ing scar from recurrent tumour following breast surgery, it can be
limited when used immediately following surgery. Interpretation of
images may be compromised because of haemorrhage.
The presence of metal clips or even tiny amounts of metal
rubbed off surgical instruments can severely reduce the image
quality caused by metal artefact (Figure 7).
FUTURE
The progression of MR technology will uncover smaller lesions
that are occult on X-ray mammography, ultrasound and clinical
evaluation. 3T systems with multichannel receivers will undoubt-
edly increase both spatial and temporal resolutions and the use of
4D sequences will provide full breast coverage. Using special pulse
sequences and a thin slice thickness, small lesions will be evaluated
using both contrast uptake and morphologic parameters. The
development of tumour-specific contrast agents may provide a
simple answer to the issues of specificity. If the nature of these
lesions cannot be clarified using noninvasive MR methods, then
the development of MR-guided biopsy or MR-guided surgery will
have to continue. However, further trials are needed as to the
clinical relevance of these very small invasive or in situ carcinomas
especially when these are multifocal.
MRI of the breast has shown great potential in the evaluation of
breast disease in research centres; however, its acceptance into
common practice is limited. This may be because of the availability
of MR systems with long waiting times in many centres. This may
improve with the introduction of additional new opportunities
funding (NOF) systems. There is also a national shortage of
radiologists, especially those who specialise in MR and breast
disease. Advances in software will enable compression of the huge
MR data sets, particularly dynamic contrast-enhanced data with
functional images corresponding to contrast uptake character-
istics. This may help to reduce the time taken to report MR breast
examinations.
The variety of scanning techniques and hardware limit
reproducible results from centre to centre. To gain widespread
usage, we must develop systems that exceed current standards of
imaging but will not require complex data analysis. We must
standardise protocols compatible with the hardware that is
available to the majority of hospitals. In the meantime, breast
MRI will continue to be regarded as a problem-solving tool.
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